Pandemic To Nearly Wipe Out Growth In Large Parts Of Asia-Pacific In 2020: Report
Developing Asia will likely clock up its weakest growth in nearly six decades this year, the Asian Development Bank (ADB) said on Thursday, as measures to contain the contagious novel coronavirus hammer economic activity. Developing Asia, a group of 45 countries in the Asia-Pacific region, is expected to post growth of just 0.1 per cent in 2020, the ADB said in a supplement to its Asian Development Outlook report issued in April, the slowest pace since 1961, before growing 6.2 per cent next year. The updated forecasts show more damage to economies in developing Asia than estimates it released it April, which predicted 2.2 per cent growth for the region in 2020.
"Economies in Asia and the Pacific will continue to feel the blow of the COVID-19 pandemic this year even as lockdowns are slowly eased and select economic activities restart in a ‘new normal' scenario," ADB Chief Economist Yasuyuki Sawada said in a statement.
"While we see a higher growth outlook for the region in 2021, this is mainly due to weak numbers this year, and this will not be a V-shaped recovery," Sawada said, as he underlined the need for governments to undertake measures to cushion the economic blow of the pandemic and prevent further waves of infections.
ADB's outlook for China this year also turned grimmer. It now expects growth in the world's second-largest economy to slow to 1.8 per cent from an earlier forecast of 2.3 per cent, with renewed escalation in US-China trade tensions also posing a downside risk.
Citing depressed demand and lower oil prices, the ADB said inflation for developing Asia will ease to 2.9 per cent for 2020, down from its 3.2 per cent forecast in April, and slow further to 2.4 per cent in 2021.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.